Gedea Biotech was on thursday evening crowned as winner of Game Changer award in Venture Cup competition Startup in Malmö. A Game Changer is an innovative startups with Potential to disrupt a current industry and the competitors were the 12 finalists chosen among close to 400 contributions. The prize was 50 000 SEK as well as gift cards from the Venture cup partnering organizations. On September 21st, the national finals in Lund awaits Gedea Biotech. Venture Cup is the competition of entrepreneurs of tomorrow, held every year since 1998.
Posted on May 19, 2017
Gedea Biotech has been granted 900.000 SEK in Vinnova's grant program for innovative startup companies. The company has also expanded the board with Mats Persson, who has over 30 years of experience in marketing and sales in life sciences. The recruitment means a valuable strengthening of the board's expertise in marketing and licensing.
Posted on November 20, 2017
The magazine Kemivärlden Biotech recently published an article about Gedea Biotech, where chairman Olov Sterner describes the driving force to find a treatment of vaginal infections which is not based on antibiotics to get around the resistance problem. The article also describes the company's current and planned development.
Posted on June 16, 2017
Gedea Biotech has been selected as one of the 12 regional finalists in Venture Cup South among close to 400 contributions. Venture Cup is the competition of entrepreneurs of tomorrow, held every year since 1998. The participating teams compete in four categories: Student Superstart, Top Tech, Game Changer and Impact Maker. The regional final in Venture Cup South will be held in Malmö on May 18th and the winners will advance to the national finals on September 21st.
Posted on May 4, 2017
CEO on Rapidus´list over talent from Skåne
Rapidus made a list of talented young professionals in the business environment in Skåne "that Stockholm based media missed". On the list is Annette Säfholm, CEO of Gedea Biotech.
Read full article here.
Posted on March 5, 2018
Gedea Biotech has raised 11 MSEK for clinical trials throughout 2018, to verify the treatment of vaginal infections. The share issue has attracted a large interest from investors and was expanded from estimated 7 MSEK to 11 MSEK.
Posted on December 20, 2017
When the 15 finalists pitched their business ideas, the audience voted to choose their favorite in Thursday's Sweden final in the Venture cup entrepreneurship competition. Gedea Biotech, received the most votes, thereby winning the Venture Cup Crowd Award, and free business trips by train in first class with SJ for one year.
Posted on September 22, 2017
http://www.smileincubator.life/mediaroom/#/publication/59c3a5746ce607000483ae55/588f096e9e9d0d0d00093271?&sh=false<iframe width="504" height="284" src="https://www.youtube.com/embed/LCRJXUTeezM" frameborder="0" allowfullscreen></iframe>
Gedea Biotech is one of 15 finalists in the national Venture cup final in Lund on September 21. The company advanced after winning Southern Sweden's semifinal in the "Game changer" class. Gedea Biotech, which develops an antibiotic-free, local treatment with a completely new mode of action for the treatment of vaginal infections, recently joined the SmiLe life science incubator in Lund.
Posted on September 21, 2017
Gedea Biotech has been selected as one of the shortlisted entrants for the Emerging Technologies Competition, a European competition organized by the Royal Society of Chemistry in collaboration with industrial partners such as AstraZeneca, Pfizer and GE Healthcare. As one of the finalists, Gedea Biotech will present the company at the Chemistry Means Business Conference in Manchester, 13-14 June, where the prize-winners will be designated. Emerging Technologies Competition is arranged for the fifth consecutive year and aims to accelerate the commercialization of innovative technologies. See more about the competition at http://www.rsc.org/competitions/emerging-technologies/shortlisted-entries-2017/#health
Posted on April 24, 2017
Things goes well for the newly started company Gedea Biotech AB. During the first months of this year, the company, which is still in an early stage, received nearly one million crowns in grants. Now awaits continued development and then clinical studies and the company expects to be able to have an efficient and safe treatment for vaginal fungal infections available on the market within a few years.
Posted on March 30, 2017
Gedea Biotech winner of Future Innovation prize
Gedea Biotech won first prize at Lund University and Sparbanksstiftelsen Finn's competition for future innovations. The award was presented at Lund University's annual Innovation kickoff. The contest was open to all students and employees at Lund University. 77 entries were received, and a few were selected to pitch in and be interviewed by a renowned jury - the competition was fierce.
Posted on March 16, 2017
Gedea Biotech receives funding from Vinnova
Vinnova has granted Gedea Biotech's application for innovative startup companies. The applications were reviewed by external assessors and Gedea Biotech was one of the selected among over 650 applicants. Gedea Biotech develops a novel treatment of vaginal candida infections. In the project a prototype of the vaginal tablet will be formulated.
Posted on March 2, 2017
LU Holding invests in new treatment for common female problems
Article written by Rapidus: http://www.rapidus.se/lu-holding-investerar-i-innovation-mot-underlivsbesvar/
Article written by Näringsliv: http://www.naringsliv.se/tidningar/2017-1/life-science/life-science/innovation-facilitates-regional-growth/
Three-quarters of all women suffer at some time of fungal infections in the genital area, which gives physical discomfort in the short term but is also likely to cause chronic problems. Now a research team at Lund University have found a naturally occurring substance, which in test tube studies have shown promising results against the right fungi. The university's holding company becomes a shareholder in a new company to bring the treatment to market
Posted on December 20, 2016
© 2017 Gedea Biotech AB, Medicon Village, Lund, Sweden